Resalis Therapeutics is a biopharmaceutical company headquartered in Turin, Italy, with scientific roots extending to Aalborg University in Denmark and Harvard Medical School in the United States. The company specializes in developing RNA-based therapies targeting the fundamental causes of complex metabolic disorders, notably obesity and fatty liver disease.

The company's lead candidate, RES-010, is an antisense oligonucleotide designed to inhibit microRNA-22 (miR-22), a key regulator of lipid metabolism implicated in metabolic disorders. By targeting miR-22, RES-010 aims to reprogram metabolic pathways, offering potential disease-modifying effects such as sustained weight loss and improved metabolic health.